Cadrenal Therapeutics, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Quang X. Pham (CEO) and John P. Sharp (Interim CFO) certified the June 30, 2026 quarterly report on August 13, 2026 under SOX 302/906 requirements. Both officers attest that disclosure controls, internal controls over financial reporting, and financial statements are effective and fairly presented. No material weaknesses or fraud involving management are disclosed. The filing contains only boilerplate SOX certifications with no substantive business, financial, or operational disclosures.
Why this rating
Standard SOX certifications are routine filings. No financial data, transactions, or business changes disclosed. Immaterial to company trajectory.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.